Abstract:Recent studies have indicated that homeobox A3 (HOXA3) functions as a carcinogen in colon cancer and the methylation level of HOXA3 is significantly increased in lung adenocarcinoma (LUAD) tissues. However, at least to the best of our knowledge, few studies to date have been performed on HOXA3 in non-small cell lung cancer (NSCLC). Therefore, further studies on HOXA3 expression in NSCLC and the potential regulatory mechanisms are urgently required. In this study, HOXA3 expression in 55 tissues of cases of NSCLC and corresponding non-lung cancer tissues was detected by reverse transcription-quantitative PCR (RT-qPCR). In addition, the clinical significance of HOXA3 expression in NSCLC was evaluated using the Cancer Genome Atlas (TCGA) database. Bioinformatics analysis was then performed to elucidate the potential molecular mechanisms of action of HOXA3. Furthermore, the potential target microRNAs (miRNAs or miRs) of HOXA3 were predicted using miRWalk2.0. Based on Gene Expression Omnibus (GEO) and TGCA databases, standardized mean difference (SMD) and sROC methods were used for meta-analyses of the expression of potential target miRNAs of HOXA3 in NSCLC to evaluate their association with HOXA3. The results revealed that the HOXA3 expression levels in NSCLC, LUAD and lung squamous cell carcinoma (LUSC) were 0.1130±0.1398, 0.1295±0.16890 and 0.0906±0.0846, respectively. These values were all decreased compared with the normal tissues (0.1877±0.1975, 0.2337±0.2405 and 0.1249±0.0873, respectively, P<0.05). The TCGA database also revealed the low expression trend of HOXA3. The downregulation of HOXA3 may play an important role in the progression and the poor prognosis of LUAD. The TCGA database also suggested that HOXA3 in LUAD and LUSC tissues exhibited certain mutational levels. In addition, the methylation levels in the NSCLC, LUAD and LUSC tissues significantly increased [NSCLC: fold change (FC), 1.3226; P<0.001; LUAD: FC, 1.2712; P<0.001; and LUSC: FC, 1.3786; P<0.001]. According to the analyses using the Kyoto Encyclopedia of Genes and Genomes (KEGG), we found that the co-expression HOXA3 genes were mainly associated with the focal adhesion signalling pathway and the ECM-receptor interaction signalling pathway. Furthermore, the predicted miRNA, miR-372-3p, exhibited a high expression in both the NSCLC and LUAD tissues (P<0.05). On the whole, the findings of this study indicate that low HOXA3 expression may play a certain role in LUAD; however, its association with LUSC still requires further investigation. HOXA3 function may be achieved through different pathways or target miRNAs. However, the specific underlying mechanisms need to be confirmed through various functional studies.

HOXA5 Indicates Poor Prognosis and Suppresses Cell Proliferation by Regulating P21 Expression in Non Small Cell Lung Cancer

Upregulation of HOXA1 Promotes Tumorigenesis and Development of Non‑small Cell Lung Cancer: A Comprehensive Investigation Based on Reverse Transcription-Quantitative Polymerase Chain Reaction and Bioinformatics Analysis.

HOXA5 Inhibits the Proliferation and Neoplasia of Cervical Cancer Cells Via Downregulating the Activity of the Wnt/β-catenin Pathway and Transactivating TP53.

HOXA5: A crucial transcriptional factor in cancer and a potential therapeutic target

SOX5 Predicts Poor Prognosis in Lung Adenocarcinoma and Promotes Tumor Metastasis Through Epithelial-Mesenchymal Transition

Increased Expression of Homeobox 5 Predicts Poor Prognosis: A Potential Prognostic Biomarker for Glioma

HOXC8 promotes proliferation and migration through transcriptional up-regulation of TGFβ1 in non-small cell lung cancer

HOXA5 Inhibits the Proliferation of Extrahepatic Cholangiocarcinoma Cells by Enhancing MXD1 Expression and Activating the P53 Pathway

MicroRNA-196a Promotes Non-Small Cell Lung Cancer Cell Proliferation and Invasion Through Targeting HOXA5

HOXA5 is a tumor suppressor gene that is decreased in gastric cancer

<i>Dlx5</i> promotes cancer progression through regulation of <i>CCND1</i> in oral squamous cell carcinoma (OSCC)

Homeobox-A13 Acts As a Functional Prognostic and Diagnostic Biomarker Via Regulating P53 and Wnt Signaling Pathways in Lung Cancer.

Comprehensive Clinical Implications of Homeobox A10 in 3,199 Cases of Non-Small Cell Lung Cancer Tissue Samples Combining Qrt-Pcr, RNA Sequencing and Microarray Data.

HOXA1 promotes epithelial-mesenchymal transition and malignant characteristics of laryngeal squamous cell carcinoma

Hoxa13 Promotes Cancer Cell Growth and Predicts Poor Survival of Patients with Esophageal Squamous Cell Carcinoma

HOXB5 Promotes the Progression of Breast Cancer Through Wnt/beta-Catenin Pathway.

Downregulation of HOXA3 in Lung Adenocarcinoma and Its Relevant Molecular Mechanism Analysed by RT-qPCR, TCGA and in Silico Analysis

Overexpression of HOXC11 homeobox gene in clear cell renal cell carcinoma induces cellular proliferation and is associated with poor prognosis

Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation

[Study of HOXA5 Gene Expression in Breast Carcinoma].

Deregulated Hoxb7 Expression Predicts Poor Prognosis Of Patients With Esophageal Squamous Cell Carcinoma And Regulates Cancer Cell Proliferation In Vitro And In Vivo